Arcellx, Inc. (NASDAQ:ACLX - Get Free Report) Director Kavita Patel sold 1,500 shares of the firm's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $64.57, for a total value of $96,855.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Kavita Patel also recently made the following trade(s):
- On Tuesday, January 14th, Kavita Patel sold 1,500 shares of Arcellx stock. The stock was sold at an average price of $65.87, for a total transaction of $98,805.00.
- On Tuesday, December 24th, Kavita Patel sold 1,500 shares of Arcellx stock. The shares were sold at an average price of $76.97, for a total value of $115,455.00.
- On Tuesday, December 3rd, Kavita Patel sold 1,500 shares of Arcellx stock. The stock was sold at an average price of $91.88, for a total value of $137,820.00.
- On Friday, November 8th, Kavita Patel sold 33,763 shares of Arcellx stock. The stock was sold at an average price of $104.14, for a total transaction of $3,516,078.82.
- On Monday, November 11th, Kavita Patel sold 15,238 shares of Arcellx stock. The stock was sold at an average price of $105.92, for a total transaction of $1,614,008.96.
Arcellx Stock Down 1.9 %
Shares of Arcellx stock traded down $1.33 during trading on Friday, reaching $66.91. 513,830 shares of the stock were exchanged, compared to its average volume of 657,766. The firm has a market cap of $3.62 billion, a price-to-earnings ratio of -94.24 and a beta of 0.29. Arcellx, Inc. has a 1 year low of $47.88 and a 1 year high of $107.37. The stock's fifty day moving average is $74.43 and its 200 day moving average is $76.81.
Arcellx (NASDAQ:ACLX - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.06. Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. The firm had revenue of $26.03 million for the quarter, compared to analysts' expectations of $35.21 million. Equities analysts forecast that Arcellx, Inc. will post -1.58 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in ACLX. KBC Group NV increased its stake in shares of Arcellx by 37.3% during the fourth quarter. KBC Group NV now owns 1,388 shares of the company's stock valued at $106,000 after purchasing an additional 377 shares in the last quarter. Quarry LP purchased a new stake in shares of Arcellx in the 3rd quarter worth approximately $125,000. Quest Partners LLC increased its position in Arcellx by 210.1% during the 3rd quarter. Quest Partners LLC now owns 1,532 shares of the company's stock valued at $128,000 after buying an additional 1,038 shares in the last quarter. Covestor Ltd raised its stake in Arcellx by 53,766.7% during the third quarter. Covestor Ltd now owns 1,616 shares of the company's stock valued at $135,000 after buying an additional 1,613 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Arcellx by 21.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,944 shares of the company's stock worth $161,000 after acquiring an additional 347 shares in the last quarter. Hedge funds and other institutional investors own 96.03% of the company's stock.
Analyst Ratings Changes
A number of analysts recently issued reports on the stock. Morgan Stanley raised their price objective on shares of Arcellx from $81.00 to $106.00 and gave the stock an "overweight" rating in a report on Wednesday, November 6th. Piper Sandler increased their price objective on Arcellx from $91.00 to $115.00 and gave the stock an "overweight" rating in a research report on Friday, November 8th. Stifel Nicolaus upped their price objective on shares of Arcellx from $83.00 to $122.00 and gave the stock a "buy" rating in a research report on Friday, October 18th. Bank of America lifted their target price on shares of Arcellx from $84.00 to $100.00 and gave the company a "buy" rating in a research report on Wednesday, November 6th. Finally, Truist Financial lifted their price objective on shares of Arcellx from $87.00 to $136.00 and gave the stock a "buy" rating in a report on Tuesday, November 12th. Thirteen equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Arcellx currently has an average rating of "Buy" and a consensus target price of $105.93.
Read Our Latest Stock Report on ACLX
About Arcellx
(
Get Free Report)
Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
Featured Articles
Before you consider Arcellx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcellx wasn't on the list.
While Arcellx currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
